Optomed Oyj, a medical technology company, manufactures and sells handheld fundus cameras and screening software in Finland, China, and internationally. The company operates through two segments, Devices and Software segments. The company develops, manufactures, and sells fundus camera products, which are used by ophthalmologists, pediatricians, endocrinologists, neurologists, and primary care professionals. It offers camera products under the Optomed Smartscope Pro, Optomed Aurora, Optomed Polaris, and Optomed Halo brands, as well as OEM cameras, including Pictor Plus, Pictor Prestige, Visuscout 100, Fundus Module 300, and Signal brand names. The company also provides Avenue Eye Screen, a workflow management software for screening and monitoring of eye diseases, such as diabetic retinopathy; Avenue Archive, an application software for displaying, archiving, and transmitting healthcare information; Avenue Telemedicine, a telemedicine solution for remote image analysis; Avenue AI, an automated diabetic retinopathy screening service; and Avenue Sync, a software solution for integrating fundus camera to the hospital image archive and worklist server. In addition, it offers Avenue Cancer Screen, a screening process management software for breast, cervical, and colorectal cancer; Optomed RIS, a software solution for healthcare imaging units for enhancing the diagnostic process and treatment decisions; Sectra PACS, a modular system optimized for use by high production healthcare providers; Optomed Service Portal, a support function for healthcare units that order and produce imaging services; Facad, a tracing software for visible light imaging and cephalometric measurements; and Sectra PACS Pathology, a digital pathology solution, which allows scanned glass slides to be distributed and diagnosed. Further, the company provides professional IT consulting services for government institutions. It sells its products and solutions through OEMs, distributors, and direct sales. The company's customers include hospitals, eye clinics, and optician chains and stores. The company was incorporated in 2004 and is headquartered in Oulu, Finland.
Optomed Dividend Announcement
• Optomed does not currently offer dividends, we're keeping a close eye on its growth potential and financial developments.
• Stay tuned for updates on Optomed dividend policy and future announcements. In the meantime, explore other dividend-yielding opportunities on our website.
Optomed Dividend History
Optomed Dividend Yield
Optomed current trailing twelve-month (TTM) dividend yield is -%. Interested in purchasing Optomed stock? Use our calculator to estimate your expected dividend yield:
Optomed Financial Ratios
Optomed Dividend FAQ
1. Growth opportunities: Companies, especially in fast-growing industries like technology, reinvest earnings into expansion, R&D, or acquisitions to fuel future growth and increase company value.
2. Tax implications: Not paying dividends can reduce the tax burden on shareholders, who may prefer to defer taxes until selling shares and realizing capital gains.
3. Investor preferences: Some investors prefer companies to reinvest profits for higher long-term returns, particularly those seeking capital appreciation over income.
4. Capital allocation priorities: Companies may allocate cash to pay down debt, fund share buybacks, or invest in projects with higher returns than dividends.
5. Market expectations: In certain sectors, like technology, reinvesting profits for growth and innovation is often prioritized over distributing dividends to shareholders.
Place an order: Use the brokerage's trading platform to place an order to buy Optomed stock.
Remember that buying stocks involves risk, and it's important to carefully consider your investment goals, risk tolerance, and conduct thorough research before making any investment decisions.